ReviewFrom α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease
Introduction
About 100 years after the publication of “An assay on Shaking Palsy” by James Parkinson in 1817, Friedrich Lewy first described the presence of intraneuronal spherical eosinophilic inclusions and thread-like neuroaxonal spheroids in the brain of Parkinson's disease (PD) patients. In a subsequent large-scale series of post-mortem examinations, Tretiakoff had found that the nucleus niger is most likely to be affected by what he called “corps de Lewy”. Nevertheless, Lewy had already described their diffuse and cortical distribution (Holdorff, 2002). Since that time, brain histopathologists have been largely engaged in the study of Lewy bodies (LB) in neuronal cell bodies and Lewy neuritis (LN) in neuronal processes in the brain of PD patients. A deeper histological analysis allowed to classify two main types of LB (Jellinger, 2009b): 1) classic brainstem LB are spherical cytoplasmic neuronal inclusions 8–30 μm in diameter with a hyaline eosinophilic core, centric lamellar bands and a narrow pale-stained halo. After ultrastructural analysis they result as membrane unbounded granulofilamentous structures. These are made up by radially arranged 7–20 nm intermediate filaments associated with granular electron-dense material and vesicular structures in a densely packed core with peripheral radially arranged filaments of 10 nm (Forno, 1996); 2) cortical LB are instead eosinophilic, rounded structures without halo which are poorly organized and composed by 7–27 nm wide filaments mostly devoid of a central core (Jellinger, 2009b).
The exact protein composition of LB remained unknown up to 1983, when Goldman et al. (1983) showed that they contained neurofilaments, as later confirmed by Schmidt et al. (1991). Subsequently, the ubiquitination of peripherally located filaments in LB was demonstrated (Kuzuhara et al., 1988, Lennox et al., 1989). Only in 1998 the main protein component of LB was identified by Spillantini et al. (1997). They found that LB are mainly constituted by fibrillary aggregates of α-synuclein, a presynaptic protein found to be mutated in some familial cases of the disease and whose function was still unknown at that time. Hence, much effort has been devoted to disclose whether α-synuclein modifications, aggregation and/or dysfunctions could be related to PD development as well as to other neurodegenerative diseases with LB pathology, such as dementia with LB (DLB), multiple system atrophy (MSA), LB dysphagia, Alzheimer's disease (AD) and its LB variant (LBVAD) (Dev et al., 2003, Spillantini and Goedert, 2000). Yet, despite the large amount of investigations aimed at defining the pathophysiological mechanisms underlying the onset of these disorders, their molecular basis still remain an unanswered conundrum.
Numerous studies have shown that α-synuclein has a critical role in the control of neuronal activity at synaptic sites. From the overview of the α-synuclein synaptic proteome and lipidome it can be inferred that α-synuclein plays central integrative functions in the brain. Indeed, it has been shown that it behaves like a molecular chaperone, interacts with lipid membranes and synaptic proteins, is involved in endoplasmic reticulum (ER)–Golgi and axonal transport and can be transmitted from cell to cell in a prion-like infective manner (Bellucci et al., 2012).
In this review, we focused our attention on recent relevant publications shading light upon a series of α-synuclein protein or lipid partners or specific α-synuclein-induced cellular pathways at both cytoplasmic, axonal or synaptic levels, which may be implicated in the onset of dopaminergic synaptic dysfunctions. By using the following keywords: α-synuclein/dopamine and synaptic dysfunction, synaptic plasticity, lipid membrane interactions, synaptic vesicle biogenesis and recycle, ER-to-Golgi vesicular transport, synaptic/axonal protein interaction we collected a series of experimental evidences supporting the hypothesis that α-synuclein pathology underlies the loss of a series of integrative neuronal functions which may significantly contribute to the induction of synaptic derangement in PD and possibly other α-synucleinopathies.
Section snippets
Structural characteristics of α-synuclein
Alpha-synuclein belongs to a family of genes which also includes β- and γ-synucleins. These proteins have a common N-terminal sequence containing a different number of repeat regions, while they differ in the C-terminal part (Bellucci et al., 2012). The sequence of α-synuclein gene (SNCA) has a high degree of conservation in numerous organisms (Clayton and George, 1998). In humans, three α-synuclein isoforms exist (Bayer et al., 1999). The most important and widely expressed isoform is the full
Parkinson's disease and other α-synucleinopathies
The term α-synucleinopathies is usually employed to describe a series of neurodegenerative diseases characterized by the presence of pathological lesions with fibrillary aggregated α-synuclein in neurons and glia. These include prevalent conditions such as PD, DLB and AD as well as rarer disorders such as MSA, neurodegeneration with brain iron accumulation type I (NBIA-I), pure autonomic failure or diffuse LB disease (Dev et al., 2003, Spillantini and Goedert, 2000, Uversky, 2007).
In these
Alpha-synuclein in synaptic physiology
Several experimental evidences support the idea that α-synuclein is able to alter synaptic physiology. In particular, a recent scientific report has described that mice lacking α-synuclein show an enhancement of a type of facilitation which reveals a form of short-term plasticity involving reorganization of pre-synaptic vesicular storage pools in the dorsal striatum: dopamine overflow following repeated, high-frequency burst stimulation of the dopaminergic pathways (Chadchankar and Yavich, 2011
Alpha-synuclein aggregation impairs synaptic activity by affecting specific molecular pathways as well as lipid and protein partners in distinct neuronal subcellular districts
In order to define whether and how α-synuclein may affect neuronal integrative functions in physiological and pathological conditions, it is essential to have a panorama of its proteome and lipidome. In particular, it seems that the specific regulatory effect of α-synuclein within the synaptic, axonal or ER–Golgi network might be lost following its pathological accumulation and aggregation. Indeed, a fine analysis of experimental data shed light upon a series of integrated pathological pathways
Cell-to-cell α-synuclein transmission: implications for synaptic dysfunctions
Post mortem evaluations have shown that the spreading of LB pathology correlates with the progression of PD, suggesting that α-synuclein increase and aggregation may contribute to neuronal degeneration (Braak et al., 2003, Halliday and McCann, 2010, Jellinger, 2009a). More recently, studies on autopsies from PD patients who had received implants from embryonic brain tissue, have shown that grafted neurons can develop LB-like aggregates a decade after transplantation, indicating that α-synuclein
Concluding remarks
From the evidences we have collected, we felt that in the human imagination α-synuclein behavior may be very similar to that of the “Sweet dancer” described by William Butler Yeats. She is an enchanting dancer. Even if you may think she is foolish following an unknown astray, you can't stop her, there's no way to understand her, other than let her finish her dance. Watching this dancer and her companions will give us much more than just halting the dance (Fig. 4 “Sweet dancer”).
Hence, to
Acknowledgments
This work was supported by a grant from the Italian Ministry of Education, University and Scientific Research—PRIN 2006, by University of Brescia Research Fund EX 60% and by the Regione Lombardia, Italy NEDD Project (CUPH81J09002660007). We thank Dr. Alessandro Fanzani for reading the manuscript.
References (241)
- et al.
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
Neuron
(2000) - et al.
Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line
Neurosci. Res.
(2011) - et al.
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Neurobiol. Dis.
(2011) - et al.
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice
Exp. Neurol.
(2008) - et al.
Endoplasmic reticulum stress reduces the export from the ER and alters the architecture of post-ER compartments
Int. J. Biochem. Cell Biol.
(2009) - et al.
Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease
Parkinsonism Relat. Disord.
(2009) - et al.
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease
Brain Res.
(2012) - et al.
Snaring the function of alpha-synuclein
Cell
(2005) - et al.
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
Neurosci. Lett.
(2006) - et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol. Aging
(2003)
Metal binding to alpha-synuclein peptides and its contribution to toxicity
Biochem. Biophys. Res. Commun.
Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein
Brain Res.
A broken alpha-helix in folded alpha-synuclein
J. Biol. Chem.
Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration
Cell
Proteasome dysfunction in aged human alpha-synuclein transgenic mice
Neurobiol. Dis.
Rabs, SNAREs and alpha-synuclein — membrane trafficking defects in synucleinopathies
Brain Res. Rev.
The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
Trends Neurosci.
Alpha-synuclein protects SH-SY5Y cells from dopamine toxicity
Biochem. Biophys. Res. Commun.
Cell systems and the toxic mechanism(s) of alpha-synuclein
Exp. Neurol.
Synthetic filaments assembled from C-terminally truncated alpha-synuclein
FEBS Lett.
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid
Am. J. Pathol.
Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease
Neurobiol. Dis.
Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes
J. Biol. Chem.
Structural and morphological characterization of aggregated species of alpha-synuclein induced by docosahexaenoic acid
J. Biol. Chem.
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons
Neurobiol. Dis.
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease
Neuropharmacology
Widespread alterations of alpha-synuclein in multiple system atrophy
Am. J. Pathol.
Conformational properties of alpha-synuclein in its free and lipid-associated states
J. Mol. Biol.
In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies
Exp. Neurol.
Characterization of a novel protein regulated during the critical period for song learning in the zebra finch
Neuron
The propagation of prion-like protein inclusions in neurodegenerative diseases
Trends Neurosci.
Alpha-synuclein potentiates Ca2 + influx through voltage-dependent Ca2 + channels
Neuroreport
Cell biology: beyond the prion principle
Nature
Review: the neuropathology, pathophysiology and genetics of multiple system atrophy
Neuropathol. Appl. Neurobiol.
Abeta, tau and alpha-synuclein and glial cells
Nihon Shinkei Seishin Yakurigaku Zasshi
Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles
Biol. Cell
Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70
FASEB J.
Synphilin-1 inhibits alpha-synuclein degradation by the proteasome
Cell. Mol. Life Sci.
Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli
J. Biol. Chem.
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
Am. J. Pathol.
Neurotransmission in Parkinson's disease: beyond dopamine
Eur. J. Neurol.
Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Nature
DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70
PLoS One
Neural expression profile of alpha-synuclein in developing human cortex
Neuroreport
Parkinson's disease: a genetic perspective
FEBS J.
The regulation of synaptic function by alpha-synuclein
Commun. Integr. Biol.
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation
J. Neurochem.
Redistribution of DAT/alpha-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson's disease
PLoS One
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease
J. Neurochem.
Type I neurodegeneration with brain iron accumulation, (NBIA-I, formerly Hallervorden–Spatz disease). Part II — neuropathologic manifestation, novel genetic aspects and pathogenesis
Neurol. Neurochir. Pol.
Cited by (88)
Genes and dietary metals in Parkinson's disease
2023, Vitamins and Minerals in Neurological DisordersNeurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions
2022, BiochimieCitation Excerpt :Among all, the lag phase acts as a rate-limiting step as some of the major structural alterations take place during it. The lag phase is the only thermodynamically favored phase because the protein becomes compacted during fibril formation, culminating in reducing the overall exposed surface [41,42]. The fibrillization is a multi-stage process, starting from the monomeric stage, progressing to the oligomeric stage, followed by protofibrils, and ending with the formation of the fibrils.
Therapeutic targeting of membrane-associated proteins in central nervous system tumors
2021, Experimental Cell ResearchWhat we can learn from iPSC-derived cellular models of Parkinson's disease
2020, Progress in Brain ResearchNeuropathology of incidental Lewy body & prodromal Parkinson’s disease
2023, Molecular Neurodegeneration